Related Experiment Video
Updated: Aug 14, 2026

Using Coculture to Detect Chemically Mediated Interspecies Interactions
Published on: October 31, 2013
Between two cultures: the expert clinician and the pharmaceutical industry
1Division of Medicine, University of Bristol. Edwin.Gale@bristol.ac.uk
Abstract:
Expert clinicians, valued for their academic status and independence, are used by the pharmaceutical industry for advice, for contract research, and as a means of conveying their message to other clinicians. Both academics and industry depend upon this interaction, but there is a fundamental clash of cultures at the interface between the two. Independence cannot be marketed for a fee, opinion too easily shades into advocacy, and secrecy and science do not mix. Formal guidelines and declarations of interest are inadequate as a means of policing an interface where undisclosed amounts of money change hands so freely. In the absence of effective sanctions, each of us must seek a personal solution to the professional and ethical issues involved.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

